Literature DB >> 10378357

Treatment of H. pylori infection: the reality.

N Vakil1.   

Abstract

Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10378357      PMCID: PMC2578890     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  15 in total

1.  Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.

Authors:  T Lind; S Veldhuyzen van Zanten; P Unge; R Spiller; E Bayerdörffer; C O'Morain; K D Bardhan; M Bradette; N Chiba; M Wrangstadh; C Cederberg; J P Idström
Journal:  Helicobacter       Date:  1996-09       Impact factor: 5.753

Review 2.  A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia.

Authors:  N J Talley
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

3.  Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin.

Authors:  R P Logan; K D Bardhan; L R Celestin; A Theodossi; K R Palmer; P I Reed; J H Baron; J J Misiewicz
Journal:  Aliment Pharmacol Ther       Date:  1995-08       Impact factor: 8.171

4.  Patient factors affecting Helicobacter pylori eradication with triple therapy.

Authors:  A F Cutler; T T Schubert
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

5.  Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

Authors:  G D Bell; K Powell; S M Burridge; A Pallecaros; P H Jones; P W Gant; G Harrison; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

6.  Factors influencing the eradication of Helicobacter pylori with triple therapy.

Authors:  D Y Graham; G M Lew; H M Malaty; D G Evans; D J Evans; P D Klein; L C Alpert; R M Genta
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

7.  Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.

Authors:  J Parsonnet; R A Harris; H M Hack; D K Owens
Journal:  Lancet       Date:  1996-07-20       Impact factor: 79.321

8.  Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

Authors:  C A McNulty; J C Dent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

9.  Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.

Authors:  P Bytzer; J M Hansen; O B Schaffalitzky de Muckadell
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

10.  Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.

Authors:  N Vakil; M B Fennerty
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

View more
  1 in total

Review 1.  Laboratory tests for the evaluation of Helicobacter pylori infections.

Authors:  R M Nakamura
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.